The Journal of Heart and Lung Transplantation
Volume 27, Issue 5 , Pages 547-553 , May 2008

Rabbit Anti-thymocyte Globulin Induction Therapy Does Not Prolong Survival After Lung Transplantation

  • Matthew G. Hartwig, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina
    • Corresponding Author InformationReprint requests: Department of Surgery, Duke University Medical Center, Box 2605, Medical Science Research Building, Box 2605, Durham, NC 27710. Telephone: 919-684-3705. Fax: 919-681-7263.
    • ,
  • Laurie D. Snyder, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
    • ,
  • James Z. Appel III, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina
    • ,
  • Ed Cantu III, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina
    • ,
  • Shu S. Lin, MD, PhD

      Affiliations

    • Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina
    • ,
  • Scott M. Palmer, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
    • ,
  • R. Duane Davis, MD

      Affiliations

    • Division of Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina

Received 8 October 2007 ,Revised 14 January 2008 ,Accepted 24 January 2008.

References 

  1. Trulock EP, Edwards LB, Taylor DO, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report—2004. J Heart Lung Transplant. 2004;23:804–815
  2. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271–281
  3. Knoop C, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004;23:159–171
  4. Hibberd PL, Snydman DR. Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin N Am. 1995;9:863–877
  5. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323:1723–1728
  6. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol. 1997;8:1771–1777
  7. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart–lung transplantation report—2006. J Heart Lung Transplant. 2006;25:880–892
  8. Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest. 1999;116:127–133
  9. Levin B, Hoppe RT, Collins G, et al. Treatment of cadaveric renal transplant recipients with total lymphoid irradiation, antithymocyte globulin, and low-dose prednisone. Lancet. 1985;2:1321–1325
  10. Kirklin JK, Bourge RC, White-Williams C, et al. Prophylactic therapy for rejection after cardiac transplantation (A comparison of rabbit antithymocyte globulin and OKT3). J Thorac Cardiovasc Surg. 1990;99:716–724
  11. Berry GJ, Brunt EM, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J Heart Lung Transplant. 1990;9:593–601
  12. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200–1208
  13. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297–310
  14. Brock MV, Borja MC, Ferber L, et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant. 2001;20:1282–1290
  15. Waddell TK, Borro JM, Roman A, et al. A double-blind randomized trial comparing basiliximab to placebo in lung transplantation. J Heart Lung Transplant. 2006;25:114
  16. Mullen JC, Oreopoulos A, Lien DC, et al. A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant. 2007;26:504–510
  17. Burton CM, Andersen CB, Jensen AS, et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant. 2006;25:638–647
  18. Hachem RR, Chakinala MM, Yusen RD, et al. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant. 2005;24:1320–1326
  19. Girgis RE, Tu I, Berry GJ, et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant. 1996;15:1200–1208
  20. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440–444
  21. Kirklin JK, Naftel DC, Levine TB, et al. Cytomegalovirus after heart transplantation (Risk factors for infection and death: a multiinstitutional study). J Heart Lung Transplant. 1994;13:394–404
  22. Palmer SM, Burch LH, Mir S, et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant. 2006;20:30–36
  23. Palmer SM, Burch LH, Trindade AJ, et al. Innate Immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171:780–785
  24. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant. 2007;7:1457–1463
  25. Mulligan MS, Wood DE. Optimizing lung transplant immunosuppression: beyond calcineurin inhibition. J Thorac Cardiovasc Surg. 2003;125:784–786
  26. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation. 1998;65:1481–1489

PII: S1053-2498(08)00103-4

doi: 10.1016/j.healun.2008.01.022

The Journal of Heart and Lung Transplantation
Volume 27, Issue 5 , Pages 547-553 , May 2008

Article Tools

* Image Usage & Resolution